Simple Summary Allogeneic stem cell transplantation (aHSCT) is the only potentially
curative treatment option for patients with high-risk myeloid malignancies. Depending on the …

Background: Patients (pts) with myeloid malignancies characterized by high risk mutations
or cytogenetics who undergo allogeneic hematopoietic cell transplantation (HCT) have poor …

Reduced intensity conditioning (RIC) and reduced toxicity conditioning (RTC) regimens
enable allogeneic hematopoietic stem cell transplantation (alloSCT) to more patients due to …

Reduced-intensity conditioning (RIC) regimens are established options for hematopoietic
stem cell transplantation (HSCT) for patients with acute myeloid leukemia (AML) and …

The fludarabine, amsacrine, and cytarabine (FLAMSA)-reduced-intensity conditioning (RIC)
protocol has been described to be effective in patients with high-risk and refractory acute …

Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning
chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity …

Busulfan/fludarabine (BuFlu) is a widely used conditioning regimen for patients with myeloid
malignancies. The sequential FLAMSA (fludarabine+ Ara-C+ amsacrine chemotherapy) …

The use of myeloablative conditioning (MAC) in the setting of active relapsed/refractory
(R/R) acute myeloid leukemia (AML) has been hindered by high historical rates of …

Sequential protocols combining salvage chemotherapy with reduced intensity conditioning
(RIC) and allogeneic hematopoietic cell transplantation (alloHCT) for high-risk acute …

The goal of this analysis was to define the role of the moderate-intensity fludarabin Ara-C
amsacrin (FLAMSA)-reduced intensity conditioning (RIC) regimen for patients with high-risk …